MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com
קישור חיצוני עבור MediWound
HaYarkon 42
Yavne, 8122745, IL
We are honored to have sponsored the European Burns Association (EBA) 3rd Educational Course in Porto! We're proud to be part of a community that’s so dedicated to improving patient outcomes and advancing medical knowledge. #EBA #BurnCare #MedicalEducation
Thank you to all the speakers, participants, and sponsors for your invaluable contributions! Your support and engagement made the 3rd Educational Course in Porto a great success!
🌟 Employee Spotlight of the Month: Menachem Saraf 🌟 This month, we’re excited to feature menachem saraf, our dedicated R&D Production & Development Supporter here at MediWound. While his title may hint at his role, Menachem does so much more. With over two years at MediWound, he has been pivotal in advancing EscharEx production and supporting MTEC trials and development. Having previously worked with TEVA Pharmaceuticals, Menachem brings a wealth of experience and dedication to our mission. Beyond his work, Menachem’s passions include sports, running, martial arts, and traveling. A family man with one child and another on the way, he values MediWound's family-oriented culture and embodies the spirit that “the more you give, the more you gain.” His professional growth here has been phenomenal, and he finds special meaning in supporting a company dedicated to developing life-saving treatments—especially for soldiers, a cause close to his heart as a former combat soldier in the IDF. Menachem’s enthusiasm and positive energy uplift our team every day. His warm smile and unyielding professionalism remind us of the value of community, purpose, and passion in the workplace. We are truly lucky to have him with us at MediWound. Thank you, Menachem, for your commitment and for inspiring us all! #MediWoundFamily #EmployeeSpotlight #LifeSavingInnovation
🚨 Join Us at EBA 2024 in Porto, Portugal – October 17-18, 2024! 🚨 MediWound is honored to be a Platinum Sponsor at this year’s European Burns Association (EBA) Congress. We invite you to meet our team and attend two exclusive workshops on Thursday, October 17: 🔹 Enzymatic Debridement with NexoBrid – The Practice 🔹 Burn Mass Casualty Incident and Medical Countermeasures We are excited to connect, share knowledge, and collaborate with professionals in the field. Let’s make a difference together! 📅 To schedule a meeting with us, please contact Torrenova Alicia or Alberto Alabastro. #EBA2024 #BurnCare #NexoBrid #EnzymaticDebridement #BurnMassCasualty #MedicalCountermeasures #PortoPortugal
🚀 We're Hiring! Pilot Operator - MS&T Team 🚀 Join our dynamic MS&T team (Manufacturing Science & Technology) and play a key role in bringing development solutions to life. We’re looking for a motivated and skilled Pilot Operator to support our manufacturing and scale-up projects. If you’re passionate about development and eager to be part of a team that’s pushing the boundaries of what's possible, we want to hear from you! Apply now: https://lnkd.in/dmb9q5iY Or tag someone who might be interested!
We're thrilled to announce our Phase II head-to-head study evaluating #EscharEx® versus collagenase ointment for treating venous leg ulcers (VLUs). This study will support EscharEx’s Biologics License Application (BLA) submission and will strengthen our commercialization strategy. In addition, we’re proud to have secured additional R&D collaborations with Solventum and Mölnlycke Health Care ensuring consistent trial quality and enhanced patient outcomes. As we advance the field of enzymatic debridement, we remain confident in EscharEx’s potential to address clinical unmet needs for patients with chronic wounds. Learn more: https://lnkd.in/dXe4Wfmv #ClinicalTrials #WoundCare #Biologics #HealthcareInnovation #EnzymaticTherapeutics #VLUs
We are excited to share a recent interview with Drug Development & Delivery, where Ofer Gonen, our CEO, provides insights into MediWound’s innovative approach to enzymatic debridement, the development of our breakthrough drug NexoBrid®, and our expanding pipeline, including EscharEx® for chronic wounds. Stay tuned as we continue to push the boundaries in wound care and develop solutions that make a real difference in patients’ lives! FINN Partners FINN Partners Israel #InnovationInHealthcare #WoundCare #Biologics #NexoBrid #EscharEx #HealthcareTransformation
We are pleased to announce that our CEO, Ofer Gonen, will be participating in a fireside chat at the 2024 Maxim Group LLC Healthcare Virtual Summit. The discussion, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET. Learn more: https://lnkd.in/dpe_Qneq #Healthcare #MaximHealthcareSummit #TissueRepair #Biotechnology
We are proud to have been a sponsor of the XVII Congress of the Polish Burn Treatment Society, held from October 3-5 in beautiful Stare Jabłonki! This annual conference brings together experts in burn treatment, including surgeons, plastic surgeons, nurses, and key representatives from leading medical units. It is always an honor to be part of such an important event, where burn care advancements and best practices are shared to improve patient outcomes. At MediWound, we are committed to supporting the burn care community and collaborating with professionals dedicated to innovative and effective burn treatments. Robert Liss Torrenova Alicia #BurnCare #BurnTreatment #Poland #PolishBurnTreatmentSociety
Wishing You a Happy, Healthy, and Sweet New Year! As we welcome Rosh Hashanah, the Jewish New Year, we at MediWound would like to extend our warmest wishes to our colleagues, partners, and friends around the world. May this year bring you and your loved ones health, happiness, and prosperity. Shana Tova U'Metuka! 🌟 #RoshHashanah #ShanaTova #HappyNewYear #Health #Innovation
This milestone not only expands treatment options for children but also enhances national preparedness for mass casualty emergencies. Thank you, Biomedical Advanced Research and Development Authority (BARDA), for your continued support in making innovative burn care more accessible! #BARDA #NexoBrid #FDAApproval #PediatricCare #BurnTreatment #HealthcareInnovation
NEXOBRID, a thermal burn medical countermeasure, from our partner MediWound, is the 94th BARDA-supported product indication to receive FDA approval. This new indication expands on the previous FDA approval for pediatrics. This therapeutic is indicated to treat children with partial thickness and/or full thickness thermal burns. Working with the American Burn Association, BARDA identified a preparedness gap for executing this critical first step in burn care during mass casualty emergencies, such as a nuclear detonation. The current standard of care for this debridement step requires highly limited surgical resources. The use of NEXOBRID, which can be applied topically at the patient’s bedside, would remove potential complications associated with surgery and free up operating rooms for other critical burn care procedures. This approval is part of ongoing national preparedness efforts to rapidly develop safe, effective medical countermeasures that are accessible to all Americans. FDA-approved products supported by BARDA, such as NEXOBRID, could improve patient outcomes during mass casualty emergencies and potentially improve the standard of routine care for pediatrics. Learn more: https://ow.ly/otFo50TuWXR